Mereo BioPharma Group plc
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and oncology. The company’s core products and services include the development of biologics and small molecules targeting severe unmet medical needs in rare genetic disorders, oncology, and immunology. Its product portfolio and pipeline feature therapeutic candidates such as SAT035, a treatment for Fanconi anemia; Bimekizumab, a monoclonal antibody targeting IL-17A and IL-17F for inflammatory diseases; and other specialty pharmaceuticals in late-stage clinical development. Mereo BioPharma operates primarily in the United Kingdom, with a global reach through strategic partnerships and collaborations. Founded in 2015 and headquartered in London, England, Mereo BioPharma recently undertook significant strategic initiatives in the last 1-2 years, including entering new partnerships and licensing agreements to bolster its clinical programs and expand its development pipeline. The company has also focused on streamlining its operations and advancing late-stage product candidates towards commercialization. Recent developments include alliance agreements to enhance their oncology and rare disease portfolios and fundings directed at accelerating clinical trials for key assets. Mereo’s business segments consist mainly of biopharmaceutical research and development, with a strong emphasis on rare and specialty diseases. Its target markets include global healthcare providers, academic institutions, biotechnology partners, and ultimately patients affected by rare and difficult-to-treat conditions. The company’s approach centers on in-licensing or acquiring late-stage product candidates and progressing them through regulatory approvals to commercial launch. Mereo BioPharma’s subsidiaries and partnerships extend its capabilities in drug development and market access, supporting its mission to deliver transformative therapies. The comprehensive product and service offerings alongside recent strategic expansions position Mereo BioPharma as a specialized player in the biotech industry focused on rare and specialty medicine segments.
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join – Contact Levi & Korsinsky
MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
MREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their Rights
MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
MREO DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
MREO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
MREO DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm
MREO FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026
DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm